Tefibazumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Clumping factor A |
| Clinical data | |
| Trade names | Aurexis |
| ATC code | none |
| Identifiers | |
| CAS Number |
521079-87-8  |
| ChemSpider | none |
| UNII |
SBO7Q9G95R |
| KEGG |
D06054  |
| Chemical and physical data | |
| Formula | C6548H10122N1730O2034S44 |
| Molar mass | 147.590 kg/mol |
| (what is this?) (verify) | |
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]
It was developed by Inhibitex.[3]
See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
References
- ↑ Clinical trial number NCT00198289 at ClinicalTrials.gov
- ↑ Pan; Lorenzotti, S.; Zoncada, A. (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
- ↑ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
This article is issued from Wikipedia - version of the 9/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.